The FDA approved Cochlear Ltd.’s Nucleus Nexa System, the first smart cochlear implant expected to launch imminently in the US, enhancing auditory device capabilities. Concurrently, FDA Commissioner Marty Makary promotes a “New FDA” vision focused on accelerating drug approvals through transparency and partnerships, including public meetings on generic drug user fee reauthorization. These regulatory moves reflect agency modernization efforts.